Ophthalmic NSAIDS as Adjuvants
The disclosure provides methods and ophthalmic NSAIDs as adjuvants to VEGF inhibitors useful for treating retinal disorders, including but not limited to wet AMD, diabetic retinopathy, diabetic macular edema, central retinal vein occlusion, and branch retinal vein occlusion.
1 . A method for increasing the interval between intravitreal injections in a patient undergoing treatment for a retinal disorder with a VEGF inhibitor to maximize visual acuity, the method comprising the step of administering to the patient in need of such treatment, an effective amount of an adjuvant comprising one or more ophthalmic NSAIDs.
2 . The method of claim 1 , wherein the retinal disorder is wet AMD, diabetic retinopathy, diabetic macular edema, central retinal vein occlusion, or branch retinal vein occlusion.
3 . The method of claim 1 , wherein the NSAID is bromfenac, diclofenac, flurbiprofen, ketorolac, nepafenac, amfenac, or indomethacin.
4 . The method of claim 3 , wherein the NSAID is bromfenac.
5 . The method of claim 1 , wherein the VEGF inhibitor is bevacizumab, ranibizumab, or pegaptanib.
6 . The method of claim 1 , wherein the NSAID is topically administered to the eye.
7 . The method of claim 1 , wherein the NSAID is administered before, during or after administration of the VEGF inhibitor.
8 . The method of claim 1 , wherein the interval between intravitreal injections is increased by one or more months.
9 . A method for decreasing the number of intravitreal injections in a patient undergoing treatment for a retinal disorder with a VEGF inhibitor to maximize visual acuity, the method comprising the step of administering to the patient in need of such treatment, an effective amount of an adjuvant comprising one or more ophthalmic NSAIDs.
10 . The method of claim 9 , wherein the retinal disorder is wet AMD, diabetic retinopathy, diabetic macular edema, central retinal vein occlusion, or branch retinal vein occlusion.
11 . The method of claim 9 , wherein the NSAID is bromfenac, diclofenac, flurbiprofen, ketorolac, nepafenac, amfenac, or indomethacin.
12 . The method of claim 11 , wherein the NSAID is bromfenac.
13 . The method of claim 9 , wherein the VEGF inhibitor is bevacizumab, ranibizumab, or pegaptanib.
14 . The method of claim 9 , wherein the NSAID is topically administered to the eye.
15 . The method of claim 1 , wherein the NSAID is administered before, during or after administration of the VEGF inhibitor.
16 . The method of claim 9 , wherein the number of intravitreal injections is decreased by about half.
17 . A method for decreasing the amount of a VEGF inhibitor administered by intravitreal injection in a patient undergoing treatment for a retinal disorder with a VEGF inhibitor to maximize visual acuity, the method comprising the step of administering to the patient in need of such treatment, an effective amount of an adjuvant comprising one or more ophthalmic NSAIDs.
18 . The method of claim 17 , wherein the retinal disorder is wet AMD, diabetic retinopathy, diabetic macular edema, central retinal vein occlusion, or branch retinal vein occlusion.
19 . The method of claim 17 , wherein the NSAID is bromfenac, diclofenac, flurbiprofen, ketorolac, nepafenac, amfenac, or indomethacin.
20 . The method of claim 19 , wherein the NSAID is bromfenac.
21 . The method of claim 17 , wherein the VEGF inhibitor is bevacizumab, ranibizumab, or pegaptanib.
22 . The method of claim 17 , wherein the NSAID is topically administered to the eye.
23 . The method of claim 17 , wherein the NSAID is administered before, during or after administration of the VEGF inhibitor.
24 . The method of claim 17 , wherein the amount of the VEGF inhibitor administered by intravitreal injection is decreased by about half.
25 . A method for decreasing the risk to a patient undergoing intravitreal treatment for a retinal disorder with a VEGF inhibitor to maximize visual acuity, the method comprising the step of administering to the patient in need of such treatment, an effective amount of an adjuvant comprising one or more ophthalmic NSAIDs.
26 . The method of claim 25 , wherein the retinal disorder is wet AMD, diabetic retinopathy, diabetic macular edema, central retinal vein occlusion, or branch retinal vein occlusion.
27 . The method of claim 25 , wherein the NSAID is bromfenac, diclofenac, flurbiprofen, ketorolac, nepafenac, amfenac, or indomethacin.
28 . The method of claim 27 , wherein the NSAID is bromfenac.
29 . The method of claim 25 , wherein the VEGF inhibitor is bevacizumab, ranibizumab, or pegaptanib.
30 . The method of claim 25 , wherein the NSAID is topically administered to the eye.
31 . The method of claim 25 , wherein the NSAID is administered before, during or after administration of the VEGF inhibitor.
32 . The method of claim 25 , wherein the risk is infection, pain, light sensitivity, vision changes, increased eye pressure, retinal detachment, vitreous floaters endopthalmitis, or thromboembolic events.